Eli Lilly and Company (LLY) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - General
Wait for pullback to $947.91. At $979.38 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $947.91 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Mounjaro and Zepbound (56.0%); Leverage penalty (D/E 1.7): -1.0.
Eli Lilly discovers and markets human pharmaceutical products in a single segment globally. Key products include Mounjaro/Zepbound (GLP-1 class, 56% of 2025 revenues), Verzenio, Trulicity, Taltz, and Jardiance, which collectively accounted for 82% of 2025 revenues.
Wait for pullback to $947.91. At $979.38 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $947.91 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Mounjaro and Zepbound (56.0%); Leverage penalty (D/E 1.7): -1.0. Chart setup: Golden cross, above all MAs, RSI 57, MACD bullish. V9 Gate blocked: R/R 0.9x at spot < 1.5 minimum. Wait for improvement. Score 6.9/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: conservative.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMounjaro and Zepbound56%10-K Item 1A: 'Mounjaro and Zepbound accounted for 56 percent of our total revenues in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·3 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $947.91. At $979.38 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $947.91 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Mounjaro and Zepbound (56.0%); Leverage penalty (D/E 1.7): -1.0. Chart setup: Golden cross, above all MAs, RSI 57, MACD bullish. V9 Gate blocked: R/R 0.9x at spot < 1.5 minimum. Wait for improvement. Target $1082.11 (+10.5%), stop $882.58 (−11.0%), Setup A.R:R 2.1:1. Score 6.9/10, moderate confidence.
Take-profit target: $1082.11 (+14.2% upside). Target $1082.11 (+10.5%), stop $882.58 (−11.0%), Setup A.R:R 2.1:1. Stop-loss: $882.58.
Concentration risk — Product: Mounjaro and Zepbound (56.0%); Leverage penalty (D/E 1.7): -1.0.
Eli Lilly and Company trades at a P/E of 33.2 (forward 21.9). TrendMatrix value score: 4.4/10. Verdict: Buy (Wait for Entry).
39 analysts cover LLY with a consensus score of 4.1/5. Average price target: $1202.
What does Eli Lilly and Company do?Eli Lilly discovers and markets human pharmaceutical products in a single segment globally. Key products include...
Eli Lilly discovers and markets human pharmaceutical products in a single segment globally. Key products include Mounjaro/Zepbound (GLP-1 class, 56% of 2025 revenues), Verzenio, Trulicity, Taltz, and Jardiance, which collectively accounted for 82% of 2025 revenues.